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Abstract
Background: Cancer is mainly a disease of older patients. In older cancer patients, additional endpoints such as
quality of survival and daily functioning might be considered equally relevant as overall or disease free survival.
However, these factors have been understudied using prospective designs focussing on older cancer patients.
Therefore, this study will focus on the impact of cancer, ageing, and their interaction on the long-term wellbeing
of older cancer patients.
Methods/Design: This study is an observational cohort study. We aim to recruit 720 cancer patients above 70
years with a new diagnosis of breast, prostate, lung or gastrointestinal cancer and two control groups: one control
group of 720 patients above 70 years without a previous diagnosis of cancer and one control group of 720 cancer
patients between 50 - 69 years newly diagnosed with breast, prostate, lung or gastrointestinal cancer. Data
collection will take place at inclusion, after six months, after one year and every subsequent year until death or end
of the study. Data will be collected through personal interviews (consisting of socio-demographic information,
general health information, a comprehensive geriatric assessment, quality of life, health locus of control and a
loneliness scale), a handgrip test, assessment of medical records, two buccal swabs and a blood sample from
cancer patients (at baseline). As an annex study, caregivers of the participants will be recruited as well. Data
collection for caregivers will consist of a self-administered questionnaire examining depression, coping, and burden.
Discussion: This extensive data collection will increase insight on how wellbeing of older cancer patients is
affected by cancer (diagnosis and treatment), ageing, and their interaction. Results may provide new insights,
which might contribute to the improvement of care for older cancer patients.
Background
To a large extent, cancer is a disease of older people [1]
and the number of older cancer patients will continue
to increase [2]. Older patients have been under-repre-
sented in clinical trials [3], which has resulted in a pau-
city of evidence-based guidelines for treatment of older
cancer patients [4]. Over the past decades progress has
been made in the field of geriatric oncology, neverthe-
less gaps remain [5].
One gap is the limited knowledge on the specific
impact of cancer diagnosis and treatment on wellbeing
or quality of survival of older cancer patients. Neverthe-
less, “prolongation of active life expectancy” or “quality
of survival” is besides prolongation of survival increas-
ingly recognised as an important treatment goal [6].
The impact of cancer diagnosis and treatment highly
depends on the age of the patient. The assessment of
ageing however is not straightforward. Chronological
age by itself is not sufficient to assess ageing [6].
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any medium, provided the original work is properly cited.Currently, one’s physiological age is best estimated by a
comprehensive geriatric assessment (CGA) [7]. A CGA
is a multidisciplinary evaluation of an older individual’s
functional status, comorbidity, cognition, psychological
status, social support, nutritional status and review of
the patient’s medications [8]. Unfortunately, a CGA is
very time consuming. Therefore, a two-step approach
using screening instruments has been suggested [9].
Examples are the abbreviated comprehensive geriatric
assessment (aCGA) [10], the Vulnerable Elders Survey
(VES-13) [11], the Groningen Frailty Index (GFI) [12],
and the G8 [13] which has been included in the EORTC
minimal Dataset [14]. However, the predictive value of
these shorter instruments remains to be demonstrated.
Next to the CGA, a person’st r u ea g ec a na l s ob e
determined by its “molecular/biological” age. From this
molecular point of view, telomere length has been
described as a measure of ageing as it reflects the organ-
ism’s age at a cellular level [15-17]. Several studies
reported a relationship between telomere length, several
age-sensitive measures, and mortality [18-21]. However,
more data are required from longitudinal studies that
assess the association between telomere length and age-
ing-related functional measures and the impact of can-
cer on these parameters.
Age associated changes are also displayed by the
immune system, which tends to result in a decreased
immune competence also known as “immunosenes-
cence” [22-24]. Currently, several longitudinal studies
focusing on the very elderly, have started to reveal
immune signatures or biomarkers of immune ageing
consisting not of a single parameter, but a cluster of
parameters increasingly recognized as an “immune risk
profile” or IRP [25-27]. These parameters (CD4/CD8 T
cell ratio < 1; cytomegalovirus (CMV) seropositivity; low
B cell numbers; poor T cell proliferative responses)
might be associated with mortality and aspects of well-
being in a geriatric population. Therefore, they might
potentially be used to identify people at risk for adverse
outcomes and consequently develop interventions to
d e l a yo rp o s t p o n et h e s ea d v e r s eo u t c o m e s .H o w e v e r ,
until now it remains to be determined whether the clus-
ter of immune parameters in the IRP have a predictive
value under any other circumstances, for instance in
elderly cancer patients. Therefore, we aim to determine
whether the IRP and other inflammatory markers (Inter-
leukin-6 (IL-6); Tumour necrosis factor-a (TNF-a); C-
reactive protein (CRP)) are associated with wellbeing/
mortality in older cancer patients.
Besides patient related characteristics, the social net-
work is a very important factor that influences the well-
being of older cancer patients. Older cancer patients
often rely on the presence of caregivers. Unfortunately,
the tasks of caregivers sometimes result in negative
consequences to the caregivers’ emotional and physical
health, which is referred to as caregiver distress [28].
From this perspective, it has been shown that caregivers
of older cancer patients are at increased risk for depres-
sion, which might result as a consequence of the burden
of providing care, but also as a result of inadequate cop-
ing mechanisms [29]. Furthermore, depression/distress
among caregivers might also negatively affect the
patients’ wellbeing. Nevertheless, information regarding
caregiver distress, burden and coping in relation with
older cancer patient characteristics and stage of the ill-
ness is still scarce. A long-term follow-up of cancer
patients and caregivers will allow us to find prognostic
factors for caregiver distress and to give incentives for
interventions. Therefore, we aim to determine the
impact of patient characteristics (such as change in well-
being, disease and treatment characteristics) and care-
giver characteristics (such as coping strategy and
perceived burden) on the occurrence of distress and
depression among caregivers.
In conclusion, this study has three major goals: 1) To
assess the impact of cancer, ageing and their interaction
on subsequent wellbeing of older cancer patients; 2) To
determine the association between different measures of
ageing (age in life years, a CGA, its screening instru-
ments, telomere length and immunological parameters)
and evaluate their ability to predict wellbeing of older
cancer patients; 3) To assess the impact of patient and
caregiver characteristics on the occurrence of caregivers’
distress.
Methods/Design
Study design and study population
KLIMOP (Dutch acronym for project on older cancer
patients in Belgium and the Netherlands) is a Belgian
and Dutch observational prospective cohort study on
older cancer patients aged 70 years and above and two
control groups; older patients aged 70 years and above
without a previous diagnosis of cancer (control for can-
cer) and cancer patients between 50 - 69 years (control
for ageing) (see Table 1). As an annex study, caregivers
of participants will be included as well.
The study population will consist of Belgian and
Dutch participants:
- Cases: 720 older persons (≥ 70 years), with a pri-
mary diagnosis of breast, prostate, lung or gastroin-
testinal cancer. Due to different procedures in the
Belgian and Dutch hospitals, prostate cancer patients
will not be included in Belgium.
- Control group 1 (control for cancer): 720 older
persons (≥ 70 years), without a previous diagnosis
of invasive cancer (except non-melanoma cancer of
the skin).
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between 50 and 69 years old, with a primary diagno-
sis of breast, prostate, lung or gastrointestinal cancer.
Prostate cancer patients will not be included in
Belgium.
The caregiver population will consist of the (potential)
caregivers of participating patients. In this study a care-
giver is defined as the person who (most often) cares for
a needy participant in his or her direct environment, or
is most likely to do so when a participant becomes
needy. The caregiver is related (family, friends, neigh-
bours, volunteer, ...) to the participant and is not a pro-
fessional caregiver [30].
Details on the in- and exclusion criteria are listed in
Table 2. Control patients who become cases (older
patients who become cancer patients) will be considered
control and case for the respective periods. Controls,
aged 70 years or older who will be diagnosed with can-
cer, other than breast, prostate, lung or gastrointestinal
cancer will drop out. If the patient indicates that there
is no caregiver, this will be recorded. If the patient indi-
cates at the first follow-up visit he/she has a caregiver,
the caregiver will be included at the first follow-up visit.
If the caregiver changes during the study, patients will
be asked to indicate the reason. No other caregiver will
be recruited.
Recruitment
Up to date, cancer patients are recruited through five
hospitals in Belgium (Jessa Ziekenhuis, Ziekenhuis Oost-
Limburg, Regionaal Ziekenhuis Sint-Trudo, Regionaal
Ziekenhuis Heilig Hart Leuven, Universitair Ziekenhuis
Leuven) and two in the Netherlands (Maastricht Univer-
sity Medical Centre and Atrium Medical Centre Park-
stad Heerlen). Older patients without cancer are
recruited through general practitioners affiliated with
the department of General Practice of the K.U.Leuven
and Maastricht University Medical Centre.
Study endpoints and data collection
The primary endpoint of this study is wellbeing of older
cancer patients in comparison with younger cancer
patients and older patients without a previous diagnosis
of cancer. As wellbeing is a very broad concept, we
defined four domains that we considered the most
important indicators of wellbeing: quality of life, depres-
sion, functional status, and comorbidity. The secondary
Table 1 Study design
KLIMOP
Cohort - Belgium Cohort - The Netherlands
Cases Control group 1 Control group 2 Cases Control group 1 Control group 2
360 Breast, lung and
gastro-intestinal
cancer patients
(≥ 70 years)
360 Patients without
a previous diagnosis
of cancer
(≥ 70 years)
360 Breast, lung and
gastro-intestinal
cancer patients
(50 - 69 years)
360 Breast, lung-, gastro-
intestinal and prostate
cancer patients
(≥ 70 years)
360 Patients without
a previous diagnosis
of cancer
(≥ 70 years)
360 Breast, lung, gastro-
intestinal and prostate
cancer patients
(50 - 69 years)
180 Caregivers 180 Caregivers 180 Caregivers 180 Caregivers 180 Caregivers 180 Caregivers
Table 2 In- and exclusion criteria
Cases: Control group 1: Control group 2: Caregivers
Cancer patients
≥ 70 years
Patients without
cancer ≥ 70 years
Cancer patients
50 - 69 years
Inclusion criteria
Consenting after being informed √√ √ √
Aged 70 years and older √√
Aged between 50 and 69 years √
Life expectancy more than 6 months
1 √√ √
Persons who have a thorough command of Dutch √√ √
Interview within three months after cancer diagnosis √√
Exclusion criteria
Persons with a formal diagnosis of dementia √√ √
Persons with a previous diagnosis of invasive cancer
2 √√ √
Persons too ill to participate
1 √√ √
1 based on the judgment of the attending doctor
2 except non-melanoma cancer of the skin
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distress is defined as the perceived burden and the
extent of depressive feelings.
The most important co-variables are ageing, patients’
characteristics, and caregivers’ characteristics. The dif-
ferent measures of ageing include age in life years,
degree of frailty measured by a CGA, the aCGA, the
VES-13, the GFI, the G8 and telomere length as a mea-
sure of cell ageing. In the future, immunological para-
meters like Interleukin-6, Tumour necrosis factor-a,C -
reactive protein, CD4/CD8 T cell ratio and/or others
linked to immunosenescence will be included in a sam-
ple of the patients. Patients’ characteristics are operatio-
nalised as personal characteristics (socio-demographic
information, distress, coping strategy, and health locus
of control), disease characteristics (type of cancer and
TNM classification), and treatment characteristics (type
of treatment, treatment completion, complications, hos-
pitalizations and complaints during treatment). Care-
givers’ characteristics are operationalised by socio-
demographic information and coping strategy.
Data collection will take place at inclusion, after six
months of follow-up, after one year of follow-up and
every subsequent year until death or end of the study
(see Figure 1). For cancer patients and older patients
without cancer, data will be collected through personal
interviews (consisting of socio-demographic information,
general health information, a comprehensive geriatric
assessment, quality of life, health locus of control and a
loneliness scale), a handgrip test, medical information
(extracted from the medical record) and two buccal
swabs. In Belgium, a baseline blood sample will be col-
lected as well for all cancer patients. The baseline inter-
view of cancer patients (≥ 70 years and 50 - 69 years)
will take place at the hospital, scheduled together with
other appointments. The baseline interview of older
patients without cancer will take place during home
visits, as well as the follow-up interviews of both cancer
and non-cancer patients. For caregivers, data will be col-
lected through self-administered questionnaires, which
are partially given to them by the patients and partially
sent by mail. A stamped envelope will be enclosed. The
content of the data collection is summarized in Table 3.
Sample size calculation
Sample size calculations were based on the primary
objective of this study: to determine the impact of can-
cer diagnosis, ageing, and their interaction on subse-
quent wellbeing of older cancer patients. Separate
instruments such as the GDS-15 measure the four
domains that we considered the most important indica-
tors of wellbeing. Therefore, the sample size was calcu-
lated for depression as a dichotomous endpoint. The
prevalence of depression has been reported to be about
25% in older cancer patients [31], while the prevalence
of depression among community-dwelling older non-
cancer patients is considerably lower (<15%) [32]. How-
ever, higher and lower prevalences of depression have
been reported as well. Therefore, we simulated a few
sample size calculations with:
- differing prevalences of depression in the control
group: ranging from 25% to 65%
- a relative risk for disease (depression) in older can-
cer patients relative to controls of 1.5
- a power to reject the null hypothesis of 80%
- a type I error probability of 0.05
- a ratio of cases versus controls of one
Assuming these specifications, the total needed sample
size was estimated between 626 patients (assuming a
prevalence of depression of 25% in the control group)
and 100 (assuming a prevalence of depression of 65% in
the control group). In comparison with other studies on
Figure 1 Study design. Only at baseline for Belgian cancer patients
Deckx et al. BMC Public Health 2011, 11:825
http://www.biomedcentral.com/1471-2458/11/825
Page 4 of 8older patients, we assumed a loss to follow-up and a
yearly mortality rate of 10% among the two control
groups and a loss-to follow-up and a yearly mortality
rate of 20% among older cancer patients [33]. Finally,
per country, a sample size of 360 cases (cancer patients
aged 70 years and older), 360 controls (group 1: cancer
patients between 50 - 69 years) and 360 controls (group
2: older patients without a previous diagnosis of cancer)
per country was proposed, enabling within-country
analyses.
Table 3 Data collection
Setting Data collection
Interview Ageing: CGA
Functional Activities of Daily Living (ADL): Barthel index [41,42]
Instrumental Activities of Daily Living (IADL): Lawton IADL scale [43]
Handgrip strength: Hydraulic Jamar hand-held dynamometer
Polypharmacy
Depression 15-item Geriatric Depression Scale (GDS-15) [44]
Cognition Mini Mental State Examination [45]
Nutritional status Participants will be asked whether they lost or gained weight in the past three months and
how much
1
Social support Questions considering the availability of a caregiver and professional care
The loneliness scale [46]
Ageing: Screening
instruments
Abbreviated CGA (aCGA) [10,47]
Vulnerable Elders Survey - 13 (VES-13) [11]
Groningen Frailty Index (GFI) [12]
G8 [13] which has been included in the EORTC minimal Dataset [14]
Quality of life EORTC QLQ-C30 [48]
Distress Distress Barometer (DB) [49]
Coping strategy The Utrecht Coping List (UCL) [50]
Opinion on health and
disease
Health Locus of control (HLoC) [51]
Medical record Survival Date of death
Comorbidity Charlston Comorbidity Index [52] + additional diseases
2
Disease characteristics Data of cancer diagnosis, TNM classification, type of cancer
Treatment characteristics Type of treatment
Completion of therapy
Complications
Complaints (e.g. fatigue, pain)
Hospitalizations
Medication
Buccal swabs Ageing: biological
parameters
Telomere length
Baseline blood
samples
3
CD4/CD8 T cell ratio, CMV status, B cell number, IL-6, TNF-a CRP etc.
Questionnaire
caregivers
Socio-demographic
information
Coping strategy of
caregiver
The Utrecht Coping List (UCL) [50]
Caregivers distress 15-item Geriatric Depression scale (GDS15) [44]
12-item Zarit Burden Inventory (ZBI) [53]
1 We decided that the extra information given by the Mini Nutritional Assessment would not outweigh the burden of 18 extra questions, including
circumferences of the calf and upper arm.
2 A limitation of the Charlston Comorbidity Index is that it does not take into account some disorders that might affect prognosis or evolution of quality of life in
cancer patients. Therefore, some additional diseases will be registered as well (parkinsonism, blood transfusions, transplantations, thromboses, lung embolisms, a
pacemaker, angina pectoris, a PCTA or a coronary bypass).
3 Only for cancer patients in Belgium
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depression as endpoint (instead of the combination of
depression and burden). The prevalence of depression
among caregivers ranges between 32 - 50% [34]. Apply-
ing the same assumptions as for older cancer patients
(relative risk of 1.5, a prevalence of depression of 25% -
55% in the control group, a power of 80% and a 0.05)
the estimated sample size was similar (626 - 100). As
some patients will not have a caregiver, we expect it fea-
sible to recruit about half of the caregivers of all partici-
pants. We expect to recruit about 550 caregivers per
country.
Ethics
The study protocol was approved by the Ethical Com-
mittee of the K.U.Leuven and U.Z.Leuven (S52097 -
ML6279) (Belgium) and by the Medical Ethics Commit-
tee of the Maastricht University Medical Centre
(NL31414.068.10) (the Netherlands). The study will be
conducted in compliance with Good Clinical Practice
guidelines Procedures (GCP), the principles of the
Declaration of Helsinki (version October 2008) and the
Belgian (law of 7 may 2004 concerning clinical trials
with humans) and Dutch (Medical Research Involving
Human Subjects Act and Personal Data Protection Act)
laws.
Data check and analysis
All interviews and other data collection (e.g. medical
information) are processed using software developed for
this project. Data is entered directly in the database
using this program. The quality of the data entry is veri-
fied by automated checking for erroneous or missing
entries. Standard statistical analyses will be used for
describing patient characteristics and comparing older
cancer patients with the two control groups at baseline
and during follow-up. When applicable more complex
statistical methods such as multivariable logistic regres-
sion, survival analysis and methods to deal with repeated
measurements will be used. In all analyses, two sided p-
values will be used at a significance level of 0.05. In all
future publications we will follow the STROBE criteria
(Strengthening The Reporting of OBservational studies
in Epidemiology) [35].
Discussion
To our knowledge, this is the first prospective cohort
study that focuses on the wellbeing of older long-term
cancer survivors. This is surprising as the number of
o l d e rc a n c e rp a t i e n t si se x p ected to increase dramati-
cally due to the ageing of the population and advances
in early detection and cancer treatments [2].
It has been repeatedly shown that older cancer
patients are “less willing to compromise their quality of
life for the potential of increased survival” [36]. Hence,
in the geriatric oncology setting, traditional endpoints as
survival might be less relevant. As suggested by Hurria
& Balducci, other endpoints such as the quality of survi-
val may be considered equally relevant [37]. However,
information on the quality of survival is lacking. Pre-
vious prospective studies that focused at aspects of qual-
ity of survival such as functional status and quality of
life had only limited follow-up. For example, three pro-
spective studies of Puts et al., Minisine et al., and Mari-
nello et al. investigated the functional status in older
cancer patients, but only until 6 months of follow-up
[38-40]. Therefore, this study is unique as we aim to
evaluate the quality of survival (here defined as well-
being) of older cancer patients for an extended period.
This study will provide insight in the evolution of well-
being (in terms of Qol, depression, functional status and
comorbidity) and the most important determinants
among older cancer survivors in comparison with
younger cancer survivors and older patients without a
previous diagnosis of cancer. We expect to find associa-
tions between different measures of ageing and well-
being of older cancer patients, which could help us
identify people that need interventions to assure quality
of survival and to tailor treatment for older cancer
patients.
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